Friday, June 9, 2023

8:00 AM - 8:30 AM Registration and welcome coffee

8:30 AM - 8:40 AM Welcome introduction by Alexandre Mebazaa (Paris, FRA)

Session 1: Cardiogenic Shock studies: high expectations for 2023

Moderated by Susanna Price (London, GBR) & Benjamin Hibbert (Ottawa, CAN)

8:40 AM - 8:50 AM Trials are important: ECLS shock Holger Thiele (Leipzig, GER)
8:50 AM - 9:00 AM Registries are important David Morrow (Boston, USA)
9:00 AM - 9:10 AM Safety is still a concern Hannah Schaubroeck (Ghent, BEL)
9:10 AM - 9:20 AM Not all Cardiogenic Shock patients are the same Sabri Soussi (Toronto, CAN)
9:20 AM - 9:30 AM DPP3 modulators Karine Bourgeois (4TEEN4, GER)
9:30 AM - 9:35 AM Nurse's perspective Carolyn Rosner (Falls Church, USA)
9:35 AM - 9:40 AM Patient perspective Rhonda Monroe (Charlotte, USA)
9:40 AM - 10:30 AM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.

10:30 AM - 10:45 AM Coffee break

Session 2: Acute Respiratory Distress Syndrome

Moderated by Diana Stanley (The Lancet Respiratory Medicine Journal, USA) & Gus Matute-Bello (NIH, USA)

10:45 AM - 10:55 AM 2023 Global definition of ARDS Lorraine Ware (Nashville, USA)
10:55 AM - 11:05 AM COVID trials changed study designs: the evidence Samuel Brown (Salt Lake City, USA)
11:05 AM - 11:15 AM Lung Division’s support mechanisms for ARDS trials and research Gus Matute-Bello (NIH, USA)
11:15 AM - 11:25 AM Results of the TESICO trial Christina Barkauskas (Durham, USA)
11:25 AM - 11:35 AM Blue Coral PETAL studies Jack Iwashyna (Baltimore, USA)
11:35 AM - 11:45 AM Precision medicine in the treatment of COVID-19 Bruno François (Limoges, FRA)
11:45 AM - 11:55 AM An Update on PANAMO and EUA for Gohibic (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated
within 48 hours of receiving IMV, or ECMO Niels Riedemann (InflaRx, GER)
11:55 AM - 12:00 PM Industry perspective Negin Hajizadeh (Bayer, USA)
12:00 PM - 12:05 PM Patient perspective Eileen Rubin (Chicago, USA)
12:05 PM - 1:00 PM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.

1:00 PM - 2:00 PM Lunch break

Session 3: Worsening Heart Failure

Moderated by Ileana Piña (FDA, USA) & Janine Pöss (Leipzig, GER)

2:00 PM - 2:10 PM Risk Stratification and Safe Early Discharge of Emergency Department Patients with Acute Heart Failure Sean Collins (Nashville, USA)
2:10 PM - 2:20 PM Early initiation of SGLT2 inhibitors to prevent WHF after Hospitalization Zachary Cox (Nashville, USA)
2:20 PM - 2:30 PM How was congestion recorded in recent clinical trials? Megan McLaughlin (San Francisco, USA)
2:30 PM - 2:40 PM Congestion areas primary endpoints Maria Rosa Costanzo (Chicago, USA)
2:40 PM - 2:50 PM Early implementation of GDMT after acute heart failure Alexandre Mebazaa (Paris, FRA)
2:50 PM - 2:55 PM Industry perspective: How to implement guidelines? Hela Ben Hamouda (Medtronic, USA)
2:55 PM - 3:00 PM Industry perspective Harjeet Caberwal (Boehringer Ingleheim, USA)
3:00 PM - 3:05 PM Industry perspective Like Jiang (AstraZeneca, USA)
3:05 PM - 3:10 PM Patient perspective Rhonda Monroe (Charlotte, USA)
3:10 PM - 4:00 PM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.

4:00 PM - 4:30 PM Coffee break

Session 4: Artificial Intelligence: a game changer in critical care

Moderated by Romain Pirracchio (San Francisco, USA) & Michael Harhay (Philadelphia, USA)

4:30 PM - 4:40 PM From AI proof of concept to proof of value: trial design to evaluate AI algorithms Romain Pirracchio (San Francisco, USA)
4:40 PM - 4:50 PM Harnessing Collective Human Intelligence and Imitation Learning to Support Clinical Decisions Gary Weissman (Philadelphia, USA)
4:50 PM - 5:00 PM Risk of algorithmic bias in critical care: how to identify it and mitigate it? Harriette Van Spall (Hamilton, CAN)
5:00 PM - 5:10 PM AI to improve peri-operative therapy Etienne Gayat (Paris, FRA)
5:10 PM - 5:20 PM Home-based diagnosis of heart failure by ultrasound & AI Alexandre Mebazaa (Paris, FRA)
5:20 PM - 5:30 PM Industry perspective Anis Ghorbel (Precisia Care, SUI)
5:30 PM - 6:30 PM Panel discussion with the above as well as FDA, EMA and NIH representatives, scientific journals & more.

6:30 PM Adjourn

6:30 PM - 8:00 PM Dinner in the Embassy of France, Washington D.C.

Saturday, June 10, 2023

8:00 AM - 8:30 AM Welcome coffee

8:30 AM - 8:35 AM Welcome introduction by Alexandre Mebazaa (Paris, FRA)

Session 5: Novelties in Sepsis and Septic Shock:
part A: Preventing organ dysfunction matters

Moderated by Nathan Nielsen (Albuquerque, USA) & Tina Chen (San Francisco, USA)

8:35 AM - 8:45 AM Revival trial: what did we learn? Peter Pickkers (Nijmegen, NED)
8:45 AM - 8.55 AM CAL02 neutralizes toxins Andre Kalil (Omaha, USA)
8:55 AM - 9:05 AM Immunosep: personalized immunotherapy Evangelos Giamarellos-Bourboulis (Athens, GRC)
9:05 AM - 9:45 AM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.

Session 5: Novelties in Sepsis and Septic Shock:
part B: IV therapies are still mandatory

Moderated by Nathan Nielsen (Albuquerque, USA) & Tina Chen (San Francisco, USA)

9:45 AM - 9:55 AM ASTONISH: nangibotide phase IIb final results Bruno François (Limoges, FRA)
9:55 AM - 10:05 AM ACCURATE: phase III design for nangibotide in Septic Shock with a precision medicine approach Mitchell Levy (Providence, USA)
10:05 AM - 10:15 AM Septic shock: BOOST Pierre-François Laterre (Brussels, BEL)
10:15 AM - 10:25 AM Septic shock: i-Micro Matthieu Legrand (San Francisco, USA)
10:25 AM - 11:00 AM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.

11:00 AM - 11:30 AM Coffee break

Session 5: Novelties in Sepsis and Septic Shock:
part C: 2023 primary endpoints in critical care trials:
organ dysfunction, or death or both?

Moderated by Lauren Sorce (Chicago, USA) & Alexandre Mebazaa (Paris, FRA)

11:30 AM - 11:40 AM Improving survival is key Lauren Sorce (Chicago, USA)
11:40 AM - 11:50 AM Industry perspective Margarita Salcedo (Inotrem, FRA)
11:50 AM - 12:00 PM Industry perspective Juliane Bernholz (AM-Pharma, NED)
12:00 PM - 12:10 PM Industry perspective Stefan Witte (Adrenomed, GER)
12:10 PM - 12:20 PM Industry perspective Valentin Curt (Eagle Pharmaceuticals, USA)
12:20 PM - 1:00 PM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.

1:00 PM Adjourn

For past editions’ scientific programs, click on the links below: